Volume 6, Issue 3 Special Edition, September 2015

Volume 6, Issue 3 Special Edition, September 2015



Nivolumab is safe and effective in patients with relapsed/refractory lymphoid malignancies and classical Hodgkin lymphoma

Longer acting agents for the treatment of bleeding disorders

New genetic variants in GFI1B discovered in patients with bleeding and platelet disorders

Polyphosphate, a modulator of hemostasis and thrombosis: a novel target for antithrombotic agents?

Management of thrombosis in Paroxysmal Nocturnal Hemoglobinuria

New treatment options for patients with inadequately controlled polycythemia vera

JAK2 inhibitor pacritinib significantly benefits patient reported outcomes in myelofibrosis

Luspatercept increases hemoglobin and decreases the transfusion need in patients with low-, and intermediate-1 myelodysplastic syndrome

Carfilzomib-dexamethasone: a new ‘best in class’ in multiple myeloma

Adding elotuzumab to standard treatment for multiple myeloma delays disease progression

Multiple myeloma is different in elderly patients

Monitoring deep response in chronic myeloid leukaemia: new methodologies and innovative technologies

Immunotherapy: a new era in the management of lymphoma and multiple myeloma?

Prevention of febrile neutropenia with prophylactic G-CSF improves outcome

Highlights in Non-Hodgkin’s Lymphoma

Advances in Acute Myeloid Leukaemia: Increased insights in chemoresistance and first randomised evidence for kinase inhibition

Venetoclax-rituximab induces deep responses in relapsed CLL

Driver mutations and their evolution in CLL

Blinatumomab: new hope for patients with relapsed/refractory acute lymphoblastic leukemia

T. Feys

Inotuzumab ozogamicin (InO) shows promising efficacy and safety in ALL

When is ponatinib a suitable treatment option for patients with chronic phase CML and how can we optimize the benefit/risk ratio?

Optimizing patient outcomes in CML